Dr. Pietrantonio on Survival Rates in Colorectal Cancer

Filippo Pietrantonio, MD
Published: Friday, Jan 13, 2017



Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer (CRC).

The survival of such patients, says Pietrantonio, is generally poor. Typically, clinical trial data show reported survival rates of up to 5 months. However, he explains, there is some heterogeneity in clinical outcomes, as some patients may actually die sooner, while other patients may have longer survivals even if their disease is defined as refractory.

In order to improve these survival rates, Pietrantonio says that identifying the correct patients that are able to receive further treatments is key. This could be accomplished mainly through clinical selection. Currently, most available drugs cannot rely on biomarkers, thus prognostic stratification is, at present, the most important thing to do.



Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer (CRC).

The survival of such patients, says Pietrantonio, is generally poor. Typically, clinical trial data show reported survival rates of up to 5 months. However, he explains, there is some heterogeneity in clinical outcomes, as some patients may actually die sooner, while other patients may have longer survivals even if their disease is defined as refractory.

In order to improve these survival rates, Pietrantonio says that identifying the correct patients that are able to receive further treatments is key. This could be accomplished mainly through clinical selection. Currently, most available drugs cannot rely on biomarkers, thus prognostic stratification is, at present, the most important thing to do.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x